Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
03:50pm, Monday, 13'th Oct 2025
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make
09:00am, Sunday, 12'th Oct 2025
Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its or
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
07:07pm, Friday, 10'th Oct 2025
Clinical-stage biotech Protagonist Therapeutics (PTGX 29.76%) was all the rage on the stock market Friday. The company's share price closed a dizzying 29.8% higher on the day, thanks to intense takeov
RTW Investments' Rod Wong: Expect more deals in biotech space
01:21pm, Friday, 10'th Oct 2025
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the secto
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
01:06pm, Friday, 10'th Oct 2025
Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
11:25am, Friday, 10'th Oct 2025
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.
Johnson & Johnson in Talks to Buy Protagonist Therapeutics
11:13am, Friday, 10'th Oct 2025
The two companies are already codeveloping a treatment for ulcerative colitis.
Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
01:08am, Thursday, 11'th Sep 2025
Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 11:30 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Di
Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript
01:39pm, Wednesday, 03'rd Sep 2025
Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conferen
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
04:05pm, Tuesday, 26'th Aug 2025
NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist (PTGX) Q2 Revenue Falls 26%
12:34am, Thursday, 07'th Aug 2025
Protagonist (PTGX) Q2 Revenue Falls 26%
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
06:25pm, Wednesday, 06'th Aug 2025
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 06'th Aug 2025
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of ico
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
07:05am, Thursday, 26'th Jun 2025
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the
Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case
05:27pm, Friday, 20'th Jun 2025
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson &
